Davis Polk advised Auris Medical Holding AG (“Auris Medical”) on its $25.1 million public offering of 5,275,000 of its common shares. The common shares are listed on the NASDAQ Global Market under the symbol “EARS.” 

Based in Zug, Switzerland, Auris Medical is a Swiss biopharmaceutical company focused on the development of novel products for the treatment of inner ear disorders. The company is currently working on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects.  

The Davis Polk corporate team included partner Sophia Hudson and associates Pedro J. Bermeo and Eileen Juyon Park. The tax team included partner Harry Ballan and associate Brian Harris. Associate Elina Teboul provided 1940 Act advice. All members of the Davis Polk team are based in the New York office.    

Copy link to share post